Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.
In the intense competition for supremacy in weight-loss and diabetes treatments, investors are faced with a significant decision in 2026 - should they invest in Eli Lilly (NYSE:LLY) or Novo Nordisk A/S (NYSE:NVO)? Both companies are currently capitalizing on the massive demand for GLP-1 medications, positioning themselves as the leading contenders in the modern healthcare landscape.
Eli Lilly, a global leader in human pharmaceuticals, focuses on high-growth areas such as oncology and immunology. The company's diverse portfolio in the U.S. is complemented by its rapid expansion into metabolic health. However, its customer concentration poses a risk, as three major wholesale distributors - McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH) - handle a significant share of its distribution and product logistics.
Novo Nordisk, on the other hand, remains a global powerhouse in insulin and obesity care. With decades of specialized expertise, this Danish company has established itself as a key player in the industry. As both companies take advantage of the soaring demand for GLP-1 medications, investors must carefully weigh the strengths and weaknesses of each company before making their investment decision in 2026.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
